| Entry |
|
|---|
| Name |
Entecavir (INN)
|
|---|
| Formula |
C12H15N5O3
|
|---|
| Exact mass |
277.1175
|
|---|
| Mol weight |
277.2792
|
|---|
| Structure |
     |
|---|
| Activity |
Antiviral agent used in treatment of hepatitis B infection [DS: H00412]
|
|---|
| Remark |
|
|---|
| Comment |
Nucleoside reverse transcriptase inhibitor (NRTI)
|
|---|
| Target |
RNA-directed DNA polymerase inhibitor |
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF10 Entecavir
D07896 Entecavir (INN)
USP drug classification [BR:br08302]
Antivirals
Antihepatitis Agents
Entecavir
D07896 Entecavir (INN)
Antiinfectives [BR:br08307]
Antivirals
Anti-HBV agent
Reverse transcriptase inhibitor (RTI)
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)
Entecavir [ATC:J05AF10]
D07896 Entecavir (INN)
 |
|---|
| Other DBs |
CAS: 142217-69-4 PubChem: DrugBank: LigandBox: NIKKAJI: |
|---|
| KCF data |
ATOM 20
1 C8y C 24.5829 -13.9364
2 C8y C 24.5548 -15.4280
3 C8y C 25.5986 -13.1882
4 N5x N 23.1983 -13.5418
5 N4y N 23.2999 -15.9446
6 N5x N 25.8020 -16.0746
7 O5x O 25.6471 -11.7934
8 N4x N 26.9425 -13.8145
9 C8x C 22.3964 -14.7711
10 C1y C 21.6240 -17.0627
11 C8y C 26.9576 -15.3264
12 C2y C 20.5182 -16.2076
13 C1x C 21.1861 -18.2445
14 N1a N 28.2430 -15.9145
15 C1y C 19.3887 -16.9598
16 C1y C 19.7884 -18.2938
17 C1b C 18.0671 -16.5208
18 O1a O 17.0064 -17.3440
19 C2a C 20.5389 -14.8099
20 O1a O 18.9332 -19.3996
BOND 22
1 1 2 2
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 2
7 3 8 1
8 4 9 2
9 10 5 1 #Up
10 6 11 2
11 10 12 1
12 10 13 1
13 11 14 1
14 12 15 1
15 13 16 1
16 15 17 1 #Up
17 17 18 1
18 5 9 1
19 8 11 1
20 15 16 1
21 12 19 2
22 16 20 1 #Down
|
|---|
